 UMIN-CTR Clinical Trial
 UMIN-CTR Clinical Trial| Unique ID issued by UMIN | UMIN000059248 | 
|---|---|
| Receipt number | R000067768 | 
| Scientific Title | A Study on the Suppression of Spasticity by Vibration Stimulation | 
| Date of disclosure of the study information | 2025/09/30 | 
| Last modified on | 2025/09/30 20:19:04 | 
A Study on the Suppression of Spasticity by Vibration Stimulation
A Study on the Suppression of Spasticity by Vibration Stimulation
A Study on the Suppression of Spasticity by Vibration Stimulation
A Study on the Suppression of Spasticity by Vibration Stimulation
| Japan | 
stroke
| Rehabilitation medicine | 
Others
NO
Spasticity is defined as a velocity-dependent increase in muscle tone accompanied by hyperreflexia. Clinical findings include increased resistance during passive movement, hyperreflexia, and clonus. Spasticity is observed in many patients after cerebrovascular disorders and impedes activities of daily living, making appropriate spasticity assessment and treatment crucial. Vibration stimulation is one treatment for spasticity, with numerous reports on its efficacy. However, there is no consensus on optimal conditions such as frequency, amplitude, or duration of vibration stimulation. It is necessary to clarify effective stimulation conditions within a short timeframe.Many reports use the Modified Ashworth Scale (MAS) to assess the effectiveness of vibration stimulation, which involves judging the resistance felt when manually moving the target joint on a 6-point scale. However, the MAS procedure is ambiguous, and the low reliability of MAS evaluation results is a concern. Quantitative evaluation is necessary to appropriately assess spasticity and clarify treatment effects.The purpose of this study is to use quantitative evaluation to analyze in detail the spasticity-suppressing effects of vibration stimulation and to clarify the optimal stimulation settings.
Efficacy
Joint resistance torque during passive ankle dorsiflexion
Interventional
Cross-over
Randomized
Individual
Single blind -investigator(s) and assessor(s) are blinded
Placebo
2
Treatment
| Device,equipment | 
Subjects capable of undergoing three-dimensional motion analysis and the 10m walking test shall undergo these gait assessments.
Measure the subject's maximum ankle dorsiflexion angle.
Position the subject in a reclining wheelchair and ensure they remain at rest.
The subject's posture shall be set with the hip joint at 45 degrees of flexion and the knee joint at 60 degrees of flexion.
Attach the iQMoS to the subject's foot.
Using the spasticity measurement device, move the subject's ankle joint twice each at low speed (5 degrees/second) and high speed (300degrees/second) up to the maximum dorsiflexion angle measured in step 1.
Remove the spasticity measurement device.
Condition 1: Apply low-frequency (30Hz), high-amplitude (2-4mm) vibration stimulation using the Power Plate pro5. 
Immediately after vibration stimulation, repeat steps 1 through 6.
Subsequently, repeat steps 1 through 6 to confirm the duration of effect.
Subjects capable of undergoing three-dimensional motion analysis and the 10m walking test shall undergo these gait assessments.
Measure the subject's maximum ankle dorsiflexion angle.
Position the subject in a reclining wheelchair and ensure they remain at rest.
The subject's posture shall be set with the hip joint at 45 degrees of flexion and the knee joint at 60 degrees of flexion.
Attach the iQMoS to the subject's foot.
Using the spasticity measurement device, move the subject's ankle joint twice each at low speed (5 degrees/second) and high speed (300degrees/second) up to the maximum dorsiflexion angle measured in step 1.
Remove the spasticity measurement device.
Apply low-frequency (91Hz) vibration stimulation with an amplitude of 1.0mm using the Handheld Massager MD-001S
Immediately after vibration stimulation, repeat steps 1 through 6.
Subsequently, repeat steps 1 through 6 to confirm the duration of effect.
| Not applicable | 
| Not applicable | 
Male and Female
Individuals who, after receiving full explanation and with full understanding, provided written consent of their own free will to participate in this study
Individuals diagnosed with central nervous system disorders
Individuals with unstable general condition
Individuals unable to understand instructions due to impaired consciousness or severe aphasia
Individuals with a history of orthopedic disorders in the ankle joint
Individuals with passive ankle dorsiflexion range of motion less than 0 degrees
Individuals deemed inappropriate by the principal investigator or co-investigator
180
| 1st name | Yohei | 
| Middle name | |
| Last name | Otaka | 
Fujita Health University Hospital
Department of Rehabilitation Medicine
4701192
1-98, Danrakegakubo, Kutsukake-cho, Toyoake City, Aichi Prefecture
0562-93-2111
otaka119@me.com
| 1st name | Toshiki | 
| Middle name | |
| Last name | Ito | 
Fujita Health University Hospital
Rehabilitation Department
4701192
1-98, Danrakegakubo, Kutsukake-cho, Toyoake City, Aichi Prefecture
0562-93-2111
toshiki.ito@fujita-hu.ac.jp
Fujita Health University
Fujita Health University
Other
Fujita Health University Hospital
1-98, Danrakegakubo, Kutsukake-cho, Toyoake City, Aichi Prefecture
0562-93-2111
toshiki.ito@fujita-hu.ac.jp
NO
| 2025 | Year | 09 | Month | 30 | Day | 
Unpublished
Open public recruiting
| 2025 | Year | 05 | Month | 20 | Day | 
| 2025 | Year | 05 | Month | 20 | Day | 
| 2025 | Year | 05 | Month | 20 | Day | 
| 2030 | Year | 10 | Month | 05 | Day | 
| 2025 | Year | 09 | Month | 30 | Day | 
| 2025 | Year | 09 | Month | 30 | Day | 
Value 
 https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067768